Clinical Trial Update: Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update on a Phase 1/2 study of combining tazemetostat with nivolumab and ipilimumab in INI1/SMARCB1-deficient and SMARCA4-deficient CNS and rha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Teratoid Rhabdoid Tumor
• Chordoma
• Epithelioid Sarcoma
• Malignant Rhabdoid Tumor
• Rhabdoid Tumor of the Kidney
• Smarca4-deficient Primary Cns Malignant Tumors
• Smarcb1-deficient Primary Cns Malignant Tumors

Drugs mentioned

• Tazemetostat (tazemetostat)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Susan Chi, MD | Conditions: Atypical Teratoid Rhabdoid Tumor, INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING